Remote Biotech research and development Jobs · Regulatory Strategy

Job listings

  • Lead and oversee the clinical development team in designing and executing all clinical studies across the full portfolio.
  • Develop and mentor medical directors, manage performance, and build organizational capability as the portfolio grows.
  • Interact with key opinion leaders, regulatory agencies, and cross-functional teams to ensure successful drug development and registration.

Iovance Biotherapeutics is the global leader in innovating, developing, and delivering tumor infiltrating lymphocyte (TIL) cell therapies for patients with solid tumors. As an end-to-end cell therapy company with centralized U.S.-based manufacturing, they serve thousands of cancer patients worldwide each year, operating with a broad patent portfolio.

  • Provide strategic statistical leadership across oncology development programs, collaborating with Clinical Development, Regulatory, Medical, Commercial, and Portfolio teams.
  • Design and validate trial types, endpoints, and innovative adaptive designs while performing sample size/power calculations and establishing go/no-go decision gates.
  • Support regulatory submissions and health authority interactions, and quantify technical success probability for pipeline prioritization.

We are a global full-service CRO specializing in clinical development and functional solutions for pharmaceutical, biotechnology, medical device, and consumer health companies. With over 4,000 professionals in more than 20 countries, we are committed to training, diversity, and accelerating innovative drug and device development.

  • Own integrated program strategy for TIL cell therapy assets across early-to-late-stage clinical development.
  • Chair cross-functional program teams, manage timelines, and translate strategy into execution.
  • Partner with senior leadership to advance programs from early studies to global regulatory submissions.

Iovance Biotherapeutics is a global leader in innovating, developing, and delivering tumor infiltrating lymphocyte (TIL) cell therapies for solid tumors. The company operates as an end-to-end cell therapy company with fully owned, centralized U.S.-based manufacturing and is committed to a diverse and inclusive work environment.